Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review

Erlotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations. The response rate to erlotinib is ~...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Clin Oncol
Autors principals: Ansari, Jawaher, Batubara, Enas, Ali, Muhammad, Farrag, Ashraf, Bashir, Farhat, Farghaly, Hussein R., Ali, Arwa M., Shaukat, Arif
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2018
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6030992/
https://ncbi.nlm.nih.gov/pubmed/29977544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1620
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars